Heart Failure
Conditions
Brief summary
The primary objective of this study is to collect sensor data from insertable cardiac monitor systems.
Detailed description
The primary objective of this study is to collect physiological measurement data and heart failure (HF) event data that will be used to design and develop new diagnostic features for the insertable cardiac monitor (ICM) systems. This study will not have pre-defined statistical endpoints. To support the primary objective, diagnostic sensor data will be compared to reference clinical testing data and heart failure decompensation events.
Interventions
DEVICEInvestigational LUX-Dx ICM Implant
All subject will receive an investigational version of the LUX-Dx ICM device.
Sponsors
Boston Scientific Corporation
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Masking description
Physiologic Sensor data will be blinded to participants and care providers. LUX-Dx ICM commercial features will be Open Label.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Patient is currently in NYHA Class II or III. * For patients with LVEF \>40% measured on most recent available echocardiography within the previous 12 months: * ONE (1) of the following echocardiography findings: LA width (diameter) \>3.8 cm, LA length \>5.0 cm, LA area \>20 cm2, LA volume \>55 ml, LA volume index \>29 ml/m2, LVH defined by septal thickness or posterior wall thickness of \>1.1 cm AND * ONE (1) of the following: Elevated BNP/NT-proBNP as defined by: BNP \>100 pg/ml or NT-proBNP \>300 pg/ml within the previous 90 days for patients not in atrial fibrillation or BNP \>300 pg/ml or NT-proBNP \>900 pg/ml for patients in atrial fibrillation at the time of screening for eligibility OR Documented heart failure hospitalization or unscheduled heart failure IV therapy in the previous 12 months * For patients with LVEF \<40% (for MI patients, measured no less than 30 days post-MI) on most recent available echocardiography within the previous 12 months: * ONE (1) of the following: Elevated BNP/NT-proBNP as defined by BNP \>150 pg/ml or NT-proBNP \>600 pg/ml within the previous 90 days for patients not in atrial fibrillation or BNP \>450 pg/ml or NT-proBNP \>1800 pg/ml for patients in atrial fibrillation at the time of screening for eligibility OR Documented heart failure hospitalization or unscheduled heart failure IV therapy in the previous 12 months * Patient is willing to be monitored in LATITUDE Clarity and use the ICM patient mobile app. * Patient is of legal age to give informed consent and is willing to participate in the trial. Key
Exclusion criteria
* Patient is currently implanted with any other active electronic medical device. * Patient has undergone a heart transplant. * Patient is currently enrolled in another investigational study (excluding registries) without prior written approval from Boston Scientific. * Patient is known to be pregnant at the time of enrollment or plans to become pregnant during study participation. * Patient is diagnosed with amyloidosis or hypertrophic cardiomyopathy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Heart Failure Event Related Data will be assessed in all subjects through collection of reportable events and subsequent adjudication by the CEC. | Through study completion of approximately 4.5 year | Heart Failure (HF) event is defined as: * HF Hospitalization: subject is admitted with a calendar date change with signs/symptoms of congestive heart failure (CHF) and receives unscheduled augmented HF therapy with oral or intravenous medications, ultrafiltration therapy or other parenteral therapy. * HF Outpatient Visit: subject has signs/symptoms of CHF, and receives unscheduled intravenous decongestive therapy in a setting that does not involve a hospitalization with a calendar date change (e.g.: ER visit, HF clinic, primary care clinic, etc.). |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORScott Solomon, MD
Brigham and Women's Hospital
PRINCIPAL_INVESTIGATORElaine Wan, MD
Columbia University
Outcome results
None listed